Welcome to BrainStorm Cell Therapeutics
BrainStorm (NASDAQ:BCLI) is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson’s Disease (PD).
BrainStorm Strengthens Executive Team: Announces the Appointment of Yoram Bibring as Chief Financial Officer
Hackensack, NJ and Petach Tikvah, Israel -- August 3, 2015 – BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has appointed Yoram Bibring as Chief Financial Officer, effective July 30, 2015. Mr. Bibring will be responsible for all corporate finance and accounting activities for BrainStorm, and will replace Ms. Alla Patlis, the Company's current interim CFO, who will resume her duties as Controller of the Company. Read More...
Click here for our Company Presentation at the Stem Cell on the Mesa meeting in San Diego, October 2013.
Click here for a summary of the data presented at the American Academy of Neurology meeting, March 2013.